Survodutide
⚠️ Structural Separation Notice
The Ageless Pep Academy is a clinical education property independent from any commerce operation. Any references in this profile to Ageless Peps product SKUs, pricing, or the agelesspeps.com domain are for completeness and transparency; they are not endorsements and do not form part of the clinical education content. Clinicians are responsible for independent verification of any product sourcing decision. The Academy's Medical Director provides editorial oversight only and does not endorse commercial products.
Dual GLP-1/glucagon receptor agonist; investigational once-weekly injectable for obesity and MASH (Boehringer Ingelheim).
Quick Facts
| Property | Value |
|---|---|
| Also Known As | BI 456906 |
| Category | Dual GLP-1/Glucagon Receptor Agonist (Metabolic) |
| Sequence | Modified peptide with GLP-1 and glucagon receptor agonist activities (proprietary; acylated for albumin binding and extended half-life) |
| Molecular Weight | ~4000 Da (estimated) |
| Molecular Formula | Not publicly disclosed |
| PubChem CID | N/A (investigational) |
| Administration | SubQ once weekly |
| Typical Dose Range | 0.6-6.0 mg once weekly (dose-escalation over 16-20 weeks) |
| Half-Life | ~6 days |
| Storage | Refrigerate 2-8C (investigational supply) |
| FDA Status | Investigational — Phase 3 (SYNCHRONIZE program for obesity); Phase 2b completed for MASH |
| WADA Status | Not listed (investigational) |
Mechanism of Action
Survodutide is a rationally designed peptide that simultaneously activates two receptors: the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). This dual agonism produces metabolic effects that exceed those achievable by GLP-1R agonism alone, by engaging fundamentally different metabolic pathways through each receptor.
GLP-1R agonism provides the established incretin effects: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite suppression through hypothalamic GLP-1R activation. These are the same mechanisms exploited by semaglutide, liraglutide, and other GLP-1 RAs.
Glucagon receptor agonism adds a mechanistically distinct metabolic dimension:
- Hepatic lipid oxidation — Glucagon activates hepatic AMPK and PPARalpha signaling, promoting beta-oxidation of fatty acids. This directly addresses hepatic steatosis and is the key mechanism for MASH/NAFLD benefit.
- Increased energy expenditure — Glucagon increases resting energy expenditure through thermogenesis, particularly in brown adipose tissue and through futile cycling pathways. This adds caloric expenditure on top of the caloric reduction from GLP-1-mediated appetite suppression.
- Amino acid metabolism — Glucagon stimulates hepatic amino acid catabolism and ureagenesis, contributing to the overall increase in energy expenditure.
The critical design challenge was balancing the opposing glycemic effects: GLP-1R agonism lowers glucose while GCGR agonism raises it (glucagon is the counter-regulatory hormone). Survodutide was selected from 19 candidate molecules based on its optimal GLP-1R:GCGR activity ratio, achieving robust weight loss and hepatic fat reduction without clinically significant hyperglycemia (PMID: 38560764 — biomarker/pharmacological profiling paper).
Survodutide is differentiated from Tirzepatide (GIP/GLP-1 dual agonist) and Retatrutide (GIP/GLP-1/glucagon triple agonist). The glucagon receptor engagement is what distinguishes survodutide from tirzepatide, while the absence of GIP agonism distinguishes it from retatrutide. Mazdutide (IBI362, Innovent/Lilly) shares the same dual GLP-1/GCGR agonist mechanism and was approved in China in 2024 for chronic weight management.
Key Research Areas
- Obesity Treatment — Phase 2 trial demonstrated up to 14.9% body weight loss at 46 weeks with the 4.8 mg dose (PMID: 38330987)
- MASH/NAFLD — Phase 2 NEJM trial showed 62% MASH resolution rate at 4.8 mg vs. 14% placebo (PMID: 38847460)
- Type 2 Diabetes — Phase 2 trial showed HbA1c reductions up to -1.71% with weight loss up to -8.7%, superior to open-label semaglutide 1.0 mg for weight loss (PMID: 38095657)
- Cardiovascular Effects — Post-hoc analysis showed significant blood pressure improvements; SYNCHRONIZE-CV outcomes trial is planned
- Hepatic Lipid Metabolism — Glucagon-mediated hepatic fat oxidation provides a mechanistic advantage for liver disease applications
Evidence Level Summary
| Evidence Type | Count | Notes |
|---|---|---|
| Human RCTs | 3 | Phase 2 (obesity, MASH, T2D) |
| Human observational | 0 | Investigational — no real-world data yet |
| Animal in vivo | 5+ | Preclinical dual-agonist pharmacology |
| In vitro | 3+ | Receptor binding, signaling characterization |
| Systematic reviews | 1 | Meta-analysis of weight loss data |
Clinical Applications
- Weight Management — Investigational; Phase 3 SYNCHRONIZE program ongoing for obesity
- NAFLD — Investigational; Phase 2 showed strong MASH resolution; glucagon component mechanistically targeted
- Type 2 Diabetes — Investigational; dual glycemic control + weight loss
- Metabolic Syndrome — Broad cardiometabolic improvements observed across Phase 2 trials
Protocols Using This Peptide
No current vault protocols include survodutide as it remains investigational. It may be incorporated into the Weight Loss Protocol and Metabolic Reset Protocol if FDA-approved.
Ageless Peps Products
- APWS-Survodutide-Vial — Survodutide 10mg Vial, $65, wholesale only (clinical label, investigational compound)
Dosing Reference
Clinical Trial Dosing (Investigational)
| Route | Dose Range | Frequency | Duration | Source |
|---|---|---|---|---|
| SubQ (Obesity) | 0.6 mg -> 4.8 mg (escalation) | Once weekly | 46 weeks (Phase 2) | PMID 38330987 |
| SubQ (MASH) | 2.4 mg, 4.8 mg, 6.0 mg | Once weekly | 48 weeks (Phase 2) | PMID 38847460 |
| SubQ (T2D) | 0.3 mg -> 4.8 mg (escalation) | Once weekly | 16 weeks (Phase 2) | PMID 38095657 |
Dose Escalation
Dose escalation occurs over 16-20 weeks depending on the target dose and indication, primarily to manage GI tolerability. The 4.8 mg dose appears to offer the best benefit-risk profile across indications; the 6.0 mg dose did not show additional efficacy in MASH and had higher discontinuation rates.
Cycling
Not applicable (chronic therapy in clinical trials).
Contraindications & Safety
- Contraindications (observed in trials): Personal/family history of MTC, MEN2 (precautionary, consistent with GLP-1 RA class)
- Common side effects: Nausea (44-66%), diarrhea (19-30%), vomiting (20-30%), decreased appetite, constipation — rates are higher than pure GLP-1 RAs, likely reflecting the glucagon component
- Drug interactions: Expected GI slowing effects on oral medication absorption (class effect)
- Pregnancy/nursing: Not studied; expected contraindication
- Special populations: Limited data; hepatic impairment studied in cirrhosis (PMID: 38857788 — survodutide PK in cirrhosis)
- Unique safety consideration: Theoretical hyperglycemia risk from glucagon agonism, though not clinically observed at therapeutic doses due to GLP-1R counterbalance
Synergistic Combinations
As an investigational dual agonist, survodutide is designed to be a monotherapy combining two mechanisms in a single molecule. Combination approaches have not been studied.
Competitive Landscape
| Agent | Mechanism | Key Differentiator |
|---|---|---|
| Semaglutide | GLP-1 only | Established safety/efficacy; approved for obesity and T2D |
| Tirzepatide | GIP/GLP-1 | Greater weight loss (~20%+); different dual mechanism |
| Retatrutide | GIP/GLP-1/Glucagon | Triple agonist; includes both GIP and glucagon |
| Survodutide | GLP-1/Glucagon | Unique glucagon-driven hepatic fat oxidation; strongest MASH data |
Related Research
| PMID | Title | Year | Study Type |
|---|---|---|---|
| 38330987 | Survodutide for obesity: Phase 2 dose-finding trial | 2024 | RCT |
| 38847460 | Phase 2 trial of survodutide in MASH and fibrosis | 2024 | RCT |
| 38095657 | Survodutide dose-response in type 2 diabetes vs. placebo and semaglutide | 2024 | RCT |
References
- PMID 38330987 — Phase 2 obesity dose-finding trial
- PMID 38847460 — Phase 2 MASH and fibrosis trial (NEJM)
- PMID 38095657 — Phase 2 T2D dose-response trial
Related
#peptide #metabolic #investigational #not-sold #subq